Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Academic Article uri icon

Overview

abstract

  • Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6 rhesus macaques with either high or low serum nAb titers from a total of 78 animals immunized with recombinant native-like (SOSIP) Env trimers. Repeat intrarectal challenge with homologous tier 2 SHIVBG505 led to rapid infection in unimmunized and low-titer animals. High-titer animals, however, demonstrated protection that was gradually lost as nAb titers waned over time. An autologous serum ID50 nAb titer of ∼1:500 afforded more than 90% protection from medium-dose SHIV infection. In contrast, antibody-dependent cellular cytotoxicity and T cell activity did not correlate with protection. Therefore, Env protein-based vaccination strategies can protect against hard-to-neutralize SHIV challenge in rhesus macaques by inducing tier 2 nAbs, provided appropriate neutralizing titers can be reached and maintained.

authors

publication date

  • December 11, 2018

Research

keywords

  • AIDS Vaccines
  • HIV
  • HIV Antibodies
  • HIV Infections
  • Simian Acquired Immunodeficiency Syndrome
  • Simian Immunodeficiency Virus
  • env Gene Products, Human Immunodeficiency Virus

Identity

PubMed Central ID

  • PMC6335502

Scopus Document Identifier

  • 85058847833

Digital Object Identifier (DOI)

  • 10.1016/j.immuni.2018.11.011

PubMed ID

  • 30552025

Additional Document Info

volume

  • 50

issue

  • 1